Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Paul B. ManningDirector | Candel TherapeuticsCADL | Open-market buy | 02/23 | 02/26 | 550,458 sh | $5.45 | $2,999,996.1 | +24.9% |
Nichols William GarrettChief Medical Officer | Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/07/28 | 25/07/30 | 937 sh | $6.98 | $6,540.26 | −1.8% |
Nichols William GarrettChief Medical Officer | Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/06/30 | 25/07/02 | 781 sh | $5.04 | $3,936.24 | −1.5% |
Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/03/18–25/03/19 | 25/03/20 | 26,172 sh2 trades | $8.77avg. | $229,620.44 | −10.4% | |
Nichols William GarrettChief Medical Officer | Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/03/18 | 25/03/20 | 45,316 sh | $8.76 | $396,968.16 | −46.3% |
Barone FrancescaChief Scientific Officer | Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/03/18 | 25/03/20 | 32,146 sh | $8.76 | $281,598.96 | −25.0% |
Candel TherapeuticsCADL | Open-market sale10b5-1 plan · Amendment | 25/03/17 | 25/03/20 | 31,278 sh | $8.82 | $275,871.96 | −26.8% | |
Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/03/17 | 25/03/19 | 31,278 sh | $8.82 | $275,871.96 | −26.8% | |
Schoch CharlesSEE REMARKS | Candel TherapeuticsCADL | Open-market sale10b5-1 plan | 25/03/17 | 25/03/19 | 5,000 sh | $8.83 | $44,150 | −11.6% |
Nichols William GarrettChief Medical Officer | Candel TherapeuticsCADL | Open-market sale | 25/01/15 | 25/01/17 | 10,428 sh | $7.23 | $75,394.44 | −11.6% |
Candel TherapeuticsCADL | Open-market sale | 25/01/15 | 25/01/17 | 21,704 sh | $7.23 | $156,919.92 | −7.9% | |
Barone FrancescaChief Scientific Officer | Candel TherapeuticsCADL | Open-market sale | 25/01/15 | 25/01/17 | 13,534 sh | $7.23 | $97,850.82 | −10.9% |
Candel TherapeuticsCADL | Open-market sale | 25/01/15 | 25/01/17 | 14,322 sh | $7.23 | $103,548.06 | −12.9% | |
Schoch CharlesSEE REMARKS | Candel TherapeuticsCADL | Open-market sale | 25/01/15 | 25/01/17 | 9,511 sh | $7.23 | $68,764.53 | −18.1% |
Nichols William GarrettChief Medical Officer | Candel TherapeuticsCADL | Open-market sale | 25/01/08 | 25/01/10 | 10,799 sh | $8.22 | $88,767.78 | −10.7% |
Candel TherapeuticsCADL | Open-market sale | 25/01/08 | 25/01/10 | 21,172 sh | $8.22 | $174,033.84 | −7.2% | |
Barone FrancescaChief Scientific Officer | Candel TherapeuticsCADL | Open-market sale | 25/01/08 | 25/01/10 | 13,673 sh | $8.22 | $112,392.06 | −9.9% |
Candel TherapeuticsCADL | Open-market sale | 25/01/08 | 25/01/10 | 14,545 sh | $8.22 | $119,559.9 | −11.6% | |
Schoch CharlesSEE REMARKS | Candel TherapeuticsCADL | Open-market sale | 25/01/08 | 25/01/10 | 9,971 sh | $8.22 | $81,961.62 | −15.9% |
Candel TherapeuticsCADL | Open-market buy | 24/12/16 | 24/12/18 | 1,250,000 sh2 trades | $6.00avg. | $7,500,000 | +2325.5% |